Cambridge-based start-up Bicycle Therapeutics has recently raised £40 million from a range of investors to bring its cancer drug candidates to clinical trials.
The company is developing a new class of drugs called ‘Bicycles’, which are based on small protein chains, or peptides, which have been chemically constrained, and have a similar shape to a bicycle wheel. They have been designed to combine the best features of small molecule and antibody based drugs. The science behind the creation of Bicycles is based on work initiated at the MRC Laboratory of Molecular Biology by Professor Sir Greg Winter, a pioneer in monoclonal antibody development and the Master of Trinity College, working together with Professor Christian Heinis from the Ecole Polytechnique Fédérale de Lausanne.
Read the full article for more details.